PHARMACOVIGILANCE: THE PATIENT ROLE

MARCO GRECO, PHD
EPF PRESIDENT - EFCCA AMBASSADOR - PRAC MEMBER
INDEX

- EUROPEAN MEDICINE AGENCY AT A GLANCE
- EMA AND PATIENTS ENGAGEMENT IN PHARMACOVIGILANCE ACTIVITIES - PRAC
- WHAT CAN PATIENT ORGANISATIONS DO
- CONCLUSION
The European Medicines Agency has been engaging in dialogue with European patients and consumers since it was founded in 1995.

As users of the medicines that the Agency evaluates, patients and consumers are key stakeholders in the Agency's work and have specific knowledge and expertise to offer.

The Agency is committed to maintaining a strong working relationship with these groups.
28+3 EEA Member States + 3,000 European experts

EU institutions: Commission - Parliament

Committee for Herbal Medicinal Products (CHMP)

Paediatric Committee (PDCO)

Committee for Human Medicinal Products (CHMP)

Committee for Orphan Medicinal Products (COMP)

Committee for Veterinary Medicinal Products (CVMP)

Committee for Advance Therapies (CAT)

Pharmacovigilance Risk Assessment Committee (PRAC)

Management Board

EMA Secretariat

HOW IS THE EMA ORGANISED?
PATIENTS AND CONSUMERS INVOLVEMENT IN EMA

- members of its committees + Management Board
- part of the scientific advisory groups;
- responding to specific requests from the Agency
- reviewing information on medicines prepared by the Agency;
- being involved in the preparation of guidelines;
- regularly taking part in Agency conferences and workshops.
PHARMACOVIGILANCE

• Committee for Medicinal Products for Human Use (ChMP)

• Pharmacovigilance Risk Assessment Committee (PRAC)
THE PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE

Mandate of the PRAC

All aspects of the risk management of the use of medicinal products including:

- the detection, assessment, minimisation and communication relating to the risk of adverse reactions, having due regard to the therapeutic effect of the medicinal product

- the design and evaluation of post-authorisation safety studies and pharmacovigilance audit
There are three levels of possible interaction:

- **Personal: Reporting** i.e Reporting of Adverse Drug Reaction
- **Writing to EMA or PRAC** about an already ongoing procedure
- **Consultation**
  - On specific requests from the Agency
  - For information review (prepared by the Agency)
  - Being involved in the preparation of guidelines
- **Representativeness of patients and patients’ organizations**
  - 1 representative
  - 1 alternate

Both appointed by the European Commission after a consultation with the EU Parliament

**Both are PATIENTS**
Patient advocacy: ensure that patient needs as a whole are taken into account in the deliberations of the Committee.

Public safety: communication on individual medicinal products should for example consider specific patient requirements.

... in concrete

• full members
• vote as all the other members
• offer a different point of view: a perspective shift
• take into deep consideration patients’ needs (also small cohort)
• make sure that the outcomes are clear and understandable as well as the related material (e.g. patients’ cards)
PATIENTS IN PRAC vs PATIENT COMMUNITY

In PRAC
Patient representative(s) share the same level of information all the other delegates have;

The patient community captures:
- The outcomes of any procedure
- A strong commitment from EMA
- The behavior of companies

Process is fast and socially shared
WHAT PATIENT ORGANISATIONS CAN DO

- Keeping themselves in the loop
- Cope with the incredible change of environment
- Structure themselves
- Make large use of the existing resources
  - EMA Formative Events
  - Second and third level organizations are usually structured for facing the new challenges
- Create strategic alliances (e.g. HCProfessionals)
CONCLUSION

• IN PHARMACOVIGILANCE
  • Patients = end-users of products: a unique position
  • Patient reports add value to pharmacovigilance:
    • Quality equal to HCP report
    • Patients can specify the circumstances
    • They often give much more detailed and nuanced descriptions
    • Patients report some different types of reactions
    • Often report earlier
    • Perceive impact and severity of reactions differently
  • Patients at EMA (2013 data)
    • Review of information for the public: 110 package leaflets, 48 European public assessment reports, 39 safety communications
    • 33 patients participated in Scientific Advisory Groups /ad-hoc meetings
    • 28 patients participated in scientific advice / protocol assistance
For more information:

THANK YOU!